Prognostic factor | Hazard ratio (95% CI) | p value |
---|---|---|
Age (years) | ||
<60 | 1 (ref) | |
60–68 | 1.01 (0.82–1.25) | 0.89 |
69–77 | 1.30 (1.06–1.59) | 0.011 |
> 78 | 2.09 (1.67–2.61) | < 0.001 |
Local tumor stage | ||
T1–3 | 1 (ref) | |
T4 | 1.46 (1.19–1.79) | < 0.001 |
ECOG | ||
0 | 1 (ref) | |
1 | 1.41 (1.06–1.88) | 0.018 |
2 | 2.94 (2.18–3.98) | < 0.001 |
Number of metastatic sites | ||
1 | 1 (ref) | |
2 | 1.37 (1.13–1.67) | 0.001 |
≥ 3 | 1.79 (1.49–2.16) | < 0.001 |
Local lymph node metastases | 1.29 (1.10–1.50) | 0.001 |
Distant lymph node metastases | 1.19 (1.01–1.41) | 0.041 |
Bone metastases | 1.21 (1.03–1.43) | 0.021 |
Liver metastases | 1.52 (1.25–1.84) | < 0.001 |
Brain metastases | 1.84 (1.28–2.63) | 0.001 |
Adrenal metastases | 1.06 (0.88–1.29) | 0.525 |
Lung metastases | 1.10 (0.94–1.29) | 0.225 |
Histology | ||
Clear cell carcinoma | 1 (ref) | |
Other | 1.54 (1.18–2.00) | 0.001 |
Not available | 2.63 (2.20–3.14) | < 0.001 |
CRP > ULN | 1.44 (1.14–1.82) | 0.002 |
Hemoglobin < LLN | 1.50 (1.25–1.80) | < 0.001 |